Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives

@article{Caldwell2003VascularEG,
  title={Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives},
  author={Ruth B. Caldwell and Manuela Bartoli and Mohamed Ali Behzadian and Azza B. El-Remessy and Mohamed Al-Shabrawey and Daniel H. Platt and Robert W. Caldwell},
  journal={Diabetes/Metabolism Research and Reviews},
  year={2003},
  volume={19}
}
Retinal neovascularization and macular edema are central features of diabetic retinopathy, the major cause of blindness in the developed world. Current treatments are limited in their efficacy and are associated with significant adverse effects. Characterization of the molecular and cellular processes involved in vascular growth and permeability has led to the recognition that the angiogenic growth factor and vascular permeability factor vascular endothelial growth factor (VEGF) plays a pivotal… Expand
Vascular endothelial growth factor and diabetic complications
TLDR
Diabetic patients have a higher risk of hypertension and proteinuria, two surrogate markers of systemic VEGF inhibition, and certain intraocular anti-VEGF treatments could have an adverse effect in this population by possibly affecting circulating and organ-specific VEGFs and VEGf receptor levels. Expand
Antivascular endothelial growth factor in diabetic retinopathy.
TLDR
A high level of V EGF has been detected in eyes presenting DME and PDR, and thereby VEGF is an attractive candidate as therapeutic target of pharmacological treatment in the management of DR. Expand
Diabetic Retinopathy and Inflammation: Novel Therapeutic Targets
TLDR
It is possible that the novel selective inhibitors of the inflammatory cascade (like angiopoietin-2, TNFα, and chemokines) may be useful therapeutic agents in the treatment of diabetic macular edema (DME), either alone or in combination with the anti-VEGF drugs. Expand
Rat strain-dependent susceptibility to ischemia-induced retinopathy associated with retinal vascular endothelial growth factor regulation.
TLDR
A single nucleotide polymorphism (SNP) at upstream stimulating factor-binding site in the VEGF promoter region between BN and SD rats was identified and found to be associated with a high susceptibility to retinal vascular leakage in BN rats. Expand
Oxidative stress modulates the expression of VEGF isoforms in the diabetic retina
Change in levels of vascular endothelial growth factors (VEGF) isoforms is a feature of diabetic retinopathy. To better characterize the expression of VEGFa and VEGF165b isoforms in the diabeticExpand
Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (macugen) in diabetic retinopathy.
TLDR
Pegaptanib, a novel RNA aptamer currently used in the treatment of agerelated macular degeneration, binds and inactivates VEGF165 and has been shown in animal models to reverse the blood-retinal barrier breakdown associated with diabetes. Expand
Long-term global retinal microvascular changes in a transgenic vascular endothelial growth factor mouse model
TLDR
Analysis of diabetic retinopathy-like changes revealed that these parameters were tightly correlated with the initial degree of vascular leakage; low levels reflected slow and limited retinal microvascular changes in mild cases and high levels reflected more rapid and extensive changes in moderate cases. Expand
Role of cytokines and trophic factors in the pathogenesis of diabetic retinopathy.
TLDR
Recent research regarding the clinical and laboratory findings of diabetic retinopathy is summarized to uncover the detailed pathogenesis of DR, which may lead to new therapeutic strategies. Expand
A flibercept regulates retinal inflammation elicited by high glucose via the PlGF/ERK pathway.
TLDR
The hypothesis that aflibercept has anti-inflammatory action through blocking of PlGF signaling and the ERK axis in an in vitro and in vivo model of DR is explored, suggesting that inhibition of Pl GF signaling, even a selective blocking, may be useful in the management of early phases of DR when the inflammatory process is largely involved. Expand
[In vitro studies on the mechanism of action of VEGF and its inhibitors].
TLDR
The influence of V EGF isoforms and the inhibitor ranibizumab on the proliferation and migration of bovine retinal microvascular endothelial cells was studied, as well as the rearrangement of tight-junction proteins after treatment of the cells with VEGF(165) and specific inhibitors. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 201 REFERENCES
Advanced glycation end products increase retinal vascular endothelial growth factor expression.
TLDR
It is found that AGEs increased VEGF mRNA levels in the ganglion, inner nuclear, and retinal pigment epithelial (RPE) cell layers of the rat retina, and AGE-induced increases in V EGF expression were dose- and time-dependent, inhibited by antioxidants, and additive with hypoxia. Expand
Vascular endothelial growth factor and its receptors in control and diabetic rat eyes.
TLDR
The changes in retinal expression of VEGF and VEGFR-2 in association with diabetes suggest a role for this pathway in diabetic retinopathy. Expand
Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.
TLDR
Three additional selective kinase inhibitors with different selectivity profiles are used to explore the signaling pathways involved in retinal NV and suggest that regardless of contributions by other growth factors, VEGF signaling plays a critical role in the pathogenesis ofretinal NV. Expand
Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox.
TLDR
Two apparently diametrically opposed therapeutic paradigms are arising for the treatment of vascular complications in diabetes, and as these divergent therapeutic modalities begin to enter the clinical arena, careful consideration of the potential risks, benefits, and interactions of the opposing regimens is required. Expand
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.
  • L. Aiello, E. Pierce, +6 authors L. Smith
  • Medicine, Biology
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1995
TLDR
VEGF's causal role in retinal angiogenesis is demonstrated and the potential of VEGF inhibition as a specific therapy for ischemic retinal disease is proved. Expand
Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat.
TLDR
Data obtained from a rodent model in which retinal neovascularization does not occur support the concept that the VEGF/VEGF receptor system is upregulated in early diabetic retinopathy. Expand
Molecular and biological properties of vascular endothelial growth factor
  • N. Ferrara
  • Biology, Medicine
  • Journal of Molecular Medicine
  • 1999
TLDR
Current evidence indicates that VEGF is essential for embryonic vasculogenesis and angiogenesis, and both therapeuticAngiogenesis using recombinant V EGF or VEGFs gene transfer and inhibition of VEGf-mediated pathological angiogenic are being pursued. Expand
The Potential Role of PKC β in Diabetic Retinopathy and Macular Edema
TLDR
Studies suggest that orally administered LY333531, a β-isoform specific PKC inhibitor, may be effective in ameliorating retinopathy progression, proliferation, and retinal vascular leakage. Expand
The potential role of PKC beta in diabetic retinopathy and macular edema.
TLDR
Studies suggest that orally administered LY333531, a beta-isoform specific PKC inhibitor, may be effective in ameliorating retinopathy progression, proliferation, and retinal vascular leakage. Expand
Suppression of diabetic retinopathy with angiopoietin-1.
TLDR
Angiopoietin-1 is identified as the first naturally occurring protein that directly protects the retinal vasculature in diabetes and is shown to prevent and reverse diabetic retinal vascular changes in both new and established diabetes. Expand
...
1
2
3
4
5
...